Abbott Laboratories (NYSE:ABT) received FDA approval to launch the Liberta RC DBS system, the world’s smallest rechargeable deep brain stimulation (DBS) device with remote programming, to treat people living with movement disorders.
The Liberta RC DBS system also requires the fewest recharges of any FDA-approved DBS system, needing only ten recharge sessions a year for most people.
Related Content: Abbott Laboratories Surpasses Q4 Sales Expectations Despite Dip In COVID-19 Testing Demand.
Abbott says the Liberta RC DBS system is the only rechargeable DBS device compatible with Abbott’s proprietary NeuroSphere Virtual Clinic, ...